MedTrace Logo

Drug Use Investigation for Toviaz

NCT01936870 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2521

Last updated 2021-06-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.

Conditions

  • Overactive Bladder (OAB)

Interventions

DRUG

Fesoterodine (Toviaz)

Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-01
Primary Completion
2016-05-19
Completion
2016-05-19

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936870 on ClinicalTrials.gov